Next Phase Newsletter

The firm is a joint venture investment vehicle established by a family office and a strategic investment partner. The firm focuses on later-stage medical device opportunities, particularly Series A and Series B companies approaching regulatory approval. The firm primarily evaluates opportunities in the United States and Western Europe, while remaining open to select companies based in Asia. Typical check sizes range from approximately $500K to $1.5M, and the firm prefers to lead transactions. The firm may also co-invest alongside affiliated investment vehicles to support later-stage, revenue-generating companies that demonstrate a clear path to exit within a relatively short time horizon. Through long-standing industry relationships, the firm helps introduce portfolio companies into a specialized medical technology ecosystem to accelerate growth and commercialization.  

The firm evaluates opportunities across medical device categories but maintains a strong focus on implantable technologies. Core areas of interest include neuromuscular and musculoskeletal indications, particularly orthopedic and spine implants. The firm also reviews opportunities in cardiology, vascular and peripheral devices, surgical technologies, and select oncology-related technologies. Companies should typically be approaching regulatory approval and demonstrate validated technology and clinical utility.  

From a company and management team perspective, the firm requires board representation and at minimum takes an observer seat in portfolio companies. The firm seeks companies with proven technology, clear regulatory pathways, and strong commercial potential within established clinical markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a family-run investment and commercialization vehicle focused on early-stage life sciences and technology opportunities. The firm is flexible in structuring transactions, with prior investments ranging from minority participation in financing rounds to in-licensing entire therapeutic programs.  

The firm specializes in therapeutic opportunities, with a particular emphasis on rare diseases. The firm prioritizes indications where the pathophysiology is well understood, the development pathway is straightforward, and there is a clearly defined unmet medical need. The firm is also attracted to opportunities that are de-risked, including reformulation strategies and drug repurposing approaches.  

From a company and management team perspective, the firm has a strong preference for experienced leadership teams with proven track records of value creation and execution.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A family office invests in both private and public life science and healthcare companies. The firm typically writes six-figure checks for companies approaching clinical development. While historically focused on North America, the firm remains open to evaluating opportunities globally. The firm invests across therapeutics, diagnostics, digital health, and medical devices.  

The firm is generally disease-agnostic, with particular interest in ophthalmology, inflammation, and dermatology. The firm is also increasingly exploring opportunities at the intersection of technology and healthcare, including AI-enabled platforms that enhance patient management and diagnostic workflows. Although oncology is not a core focus, the firm may selectively evaluate certain indications.  

From a stage perspective, the firm reviews opportunities as early as pre-IND and generally prefers programs through Phase II development. The firm seeks evidence of technical and regulatory de-risking, including proof-of-concept data, early efficacy signals, and clearly defined regulatory pathways.  

The firm does not impose strict requirements on company or management team composition but values teams that demonstrate regulatory expertise and the ability to execute within clinical and compliance-driven environments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a publicly listed global biopharmaceutical company headquartered in Asia with a strong presence across major international markets. The firm is recognized for its capabilities in large-scale biologics development and manufacturing and has built a substantial commercial footprint worldwide. The firm pursues external innovation through equity investments, research collaborations, and in-licensing arrangements to strengthen and diversify its pipeline.  

The firm operates broadly across therapeutics and biopharmaceutical innovation, with established expertise in antibody-based medicines, follow-on biologics, and next-generation biologic platforms. The firm continues to expand into novel therapeutic programs across immunology, oncology, infectious diseases, and other high-need areas. In addition to maintaining a portfolio of established biologic products, the firm is actively enhancing its innovative pipeline through internal research, strategic partnerships, and selective in-licensing of differentiated biologic assets, including immune-modulating therapies and advanced antibody formats. The firm is open to opportunities across development stages, with interest in early and mid-stage programs.  

The firm seeks partnerships that align with its long-term biologics strategy and leverage its global development, regulatory, and manufacturing infrastructure. The firm evaluates opportunities based on strong scientific rationale, differentiated clinical positioning, scalable manufacturing feasibility, and global market potential. The firm prefers to collaborate with teams that demonstrate rigorous data generation, defensible intellectual property, and the operational capability to execute international development and commercialization strategies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 
 The firm is a global venture capital firm headquartered in Asia, with investment activity spanning Asia and the United States. The firm has raised multiple funds and recently launched a dedicated vehicle focused on biotechnology and medical technology innovation. The firm invests from Seed through early-growth stages and has backed a broad portfolio of healthcare companies. The firm deploys equity capital and works closely with founders to support global expansion, leveraging cross-border operating presence and networks across Asia and North America.  

The firm focuses on biotechnology, medical technology, and enabling platforms addressing major unmet needs in human health. The firm invests in breakthrough science and engineering-driven innovation, including therapeutics, medtech devices, diagnostics, digital health, research tools, and frontier health technologies. The firm follows a cross-border strategy that sources scientific breakthroughs from both Eastern and Western ecosystems, particularly opportunities facing market fragmentation or structural barriers that may limit global scale. The firm emphasizes companies with strong scientific foundations, differentiated clinical or technical positioning, and opportunities that can benefit from accelerated development and market access through Asian clinical, talent, and supply chain ecosystems.  

From a company and management team perspective, the firm partners with founders who demonstrate deep scientific or medical expertise, strong execution capability, and readiness for global expansion. The firm actively supports teams through hands-on venture building and provides access to clinical resources, supply networks, operating talent, and cross-border strategic guidance. The firm collaborates with companies from early stages through exit, aligning with founders to pursue global outcomes including IPOs, M&A, and strategic partnerships. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is the corporate venture capital arm of a diversified industrial group and invests globally from Seed through Series A. The firm typically deploys between USD $250K and $4M per investment. The firm focuses on equity investments and strategic partnerships that complement the parent organization’s healthcare and consumer health activities. The firm invests on a geographically agnostic basis and has recently increased its focus on opportunities in the United States. 

Approximately half of the firm’s investments are allocated to healthcare, centered on three primary pillars: medical devices, therapeutic technologies, and digital health. The firm invests in technology-driven solutions aligned with the broader healthcare ecosystem, including innovations in wound care, diagnostics, telehealth, and other patient-facing or clinical-efficiency solutions. The firm also leverages an in-house teleconsultation platform to support digital health innovation and partnership development. 

From a company and management team perspective, the firm invests in early-stage businesses with strong technological differentiation, clear clinical or operational value propositions, and the ability to scale globally. The firm seeks founders with demonstrated domain expertise and the capacity to execute product development and commercialization strategies within regulated environments. The firm participates flexibly across rounds, acting as a lead, co-lead, or co-investor, and engages with teams that can benefit from the parent organization’s healthcare infrastructure, commercial networks, and international expansion capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a private investment vehicle established in 2023 and is headquartered in Asia. The firm is focused on global healthcare opportunities. The firm co-invests in Pre-Seed through Series A rounds and currently maintains a small but diversified portfolio across biotech, digital health, and medical devices. Initial check sizes are flexible, with the firm typically allocating up to approximately USD $400K in Seed rounds and USD $1–2M in Series A financings. 

The firm is open to investing across biotech, first-in-class therapeutics, medical devices, digital health, and diagnostics. The firm is indication- and technology-agnostic but prioritizes next-generation and highly innovative technologies with strong differentiation. 

The firm does not impose strict requirements on companies or management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology